| Symbol | DARE |
|---|---|
| Name | DARE BIOSCIENCE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3655 NOBEL DRIVE,SUITE 260, SAN DIEGO, California, 92122, United States |
| Telephone | +1 858 - 926-7655 |
| Fax | — |
| — | |
| Website | https://www.darebioscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001401914 |
| Description | Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for womens health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize womens health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The companys first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The companys portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Additional info from NASDAQ: |
New Form DEFA14A - Dare Bioscience, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001401914-26-000016 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Dare Bioscience, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001401914-26-000014 <b>Size:</b> 3 MB
Read more(99% Neutral) DARE BIOSCIENCE, INC. (DARE) Announces New Board Appointment
Read moreNew Form PRE 14A - Dare Bioscience, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001401914-26-000009 <b>Size:</b> 3 MB
Read moreNew Form QUALIF - Dare Bioscience, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 9999999994-26-000077 <b>Size:</b> 1 KB
Read more(10% Negative) DARE BIOSCIENCE, INC. (DARE) Announces Delay in results Trials for earnest now Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreNew Form 10-K - Dare Bioscience, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001401914-26-000004 <b>Size:</b> 11 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06668896 | Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vag… | Phase1 | Pre Term Birth | Not_Yet_Recruiting | 2025-11-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT06127199 | Contraceptive Efficacy Study of Ovaprene | Na | Contraception | Recruiting | 2023-12-19 | 2026-09-01 | ClinicalTrials.gov |
| NCT05752526 | A Study of Diclofenac Gel in Women With Primary Dysmenorrhea | Phase1 | Dysmenorrhea Primary | Completed | 2023-05-19 | 2024-04-26 | ClinicalTrials.gov |
| NCT05765487 | Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% | Phase1 | Sexual Arousal Disorder | Completed | 2023-05-13 | 2024-10-21 | ClinicalTrials.gov |
| NCT05367973 | Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women | Phase1 | Vulvovaginal Atrophy | Completed | 2022-04-11 | 2023-03-23 | ClinicalTrials.gov |
| NCT05378269 | Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA | Phase1 | Vulvar Atrophy | Completed | 2021-11-22 | 2023-03-01 | ClinicalTrials.gov |
| NCT04948151 | Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6… | Phase2 | Female Sexual Arousal Disorder | Unknown | 2021-06-28 | 2021-12-15 | ClinicalTrials.gov |
| NCT05354050 | Pharmacokinetic Study of DARE-BV1 | Phase1 | Bacterial Vaginosis | Completed | 2020-11-03 | 2020-12-02 | ClinicalTrials.gov |
| NCT05418426 | A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics an… | Phase1 | Vulvovaginal Atrophy | Completed | 2020-08-18 | 2022-01-27 | ClinicalTrials.gov |
| NCT04370548 | DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) | Phase3 | Bacterial Vaginosis | Completed | 2020-06-16 | 2020-12-07 | ClinicalTrials.gov |
| NCT03598088 | Safety and Acceptability Study of a Non-Hormonal Ring | Na | Contraception | Completed | 2018-05-23 | 2019-11-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Female Sexual Arousal Disorder | UNKNOWN | NCT04948151 |
| Sildenafil | Other | Phase PHASE2 | Female Sexual Arousal Disorder | UNKNOWN | NCT04948151 |
| IVR Dose 2 | Other | Phase PHASE1 | Vulvovaginal Atrophy | COMPLETED | NCT05367973 |
| IVR Dose 1 | Other | Phase PHASE1 | Vulvovaginal Atrophy | COMPLETED | NCT05367973 |
| DARE-BV1 | Other | Phase PHASE1 | Bacterial Vaginosis | COMPLETED | NCT05354050 |
| Ovaprene | Other | Approved | Contraception | COMPLETED | NCT03598088 |
| DARE-BV1clindamycin phosphate vaginal gel, 2% | Other | Phase PHASE3 | Bacterial Vaginosis | COMPLETED | NCT04370548 |
| Oral Reference | Other | Phase PHASE1 | Vulvovaginal Atrophy | COMPLETED | NCT05418426 |
| IVR Dose 2 | Other | Phase PHASE1 | Vulvovaginal Atrophy | COMPLETED | NCT05418426 |
| IVR Dose 1 | Other | Phase PHASE1 | Vulvovaginal Atrophy | COMPLETED | NCT05418426 |
| Placebo | Other | Phase PHASE1 | Vulvar Atrophy | COMPLETED | NCT05378269 |
| Tamoxifen | Other | Phase PHASE1 | Vulvar Atrophy | COMPLETED | NCT05378269 |
| Placebo | Other | Phase PHASE1 | Sexual Arousal Disorder | COMPLETED | NCT05765487 |
| Vehicle | Other | Phase PHASE1 | Sexual Arousal Disorder | COMPLETED | NCT05765487 |
| Sildenafil | Other | Phase PHASE1 | Sexual Arousal Disorder | COMPLETED | NCT05765487 |
| Placebo | Other | Phase PHASE1 | Dysmenorrhea Primary | COMPLETED | NCT05752526 |
| Diclofenac 3% | Other | Phase PHASE1 | Dysmenorrhea Primary | COMPLETED | NCT05752526 |
| Diclofenac 1% | Other | Phase PHASE1 | Dysmenorrhea Primary | COMPLETED | NCT05752526 |
| Progesterone | Other | Phase PHASE1 | Pre Term Birth | NOT_YET_RECRUITING | NCT06668896 |
| Ovaprene | Other | Approved | Contraception | RECRUITING | NCT06127199 |